Develops precision cancer medicines for underserved patients.
Jun 2026Revenue $22.4M/yrExpenses $89.8M/yr
No trendCash runway ≈ 4.6 years from Jun 2026
Figures by year
When will Prelude Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $22.4M and expenses $89.8M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $12.1M | $117M | −$105M |
| Dec 2024 | $7.00M | $147M | −$140M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.